Literature DB >> 31180719

Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Melissa J Alldred1,2, Helen M Chao1,2, Sang Han Lee3,4, Judah Beilin1, Brian E Powers5, Eva Petkova6,7, Barbara J Strupp5,8, Stephen D Ginsberg1,2,4,9.   

Abstract

Choline is critical for normative function of 3 major pathways in the brain, including acetylcholine biosynthesis, being a key mediator of epigenetic regulation, and serving as the primary substrate for the phosphatidylethanolamine N-methyltransferase pathway. Sufficient intake of dietary choline is critical for proper brain function and neurodevelopment. This is especially important for brain development during the perinatal period. Current dietary recommendations for choline intake were undertaken without critical evaluation of maternal choline levels. As such, recommended levels may be insufficient for both mother and fetus. Herein, we examined the impact of perinatal maternal choline supplementation (MCS) in a mouse model of Down syndrome and Alzheimer's disease, the Ts65Dn mouse relative to normal disomic littermates, to examine the effects on gene expression within adult offspring at ∼6 and 11 mo of age. We found MCS produces significant changes in offspring gene expression levels that supersede age-related and genotypic gene expression changes. Alterations due to MCS impact every gene ontology category queried, including GABAergic neurotransmission, the endosomal-lysosomal pathway and autophagy, and neurotrophins, highlighting the importance of proper choline intake during the perinatal period, especially when the fetus is known to have a neurodevelopmental disorder such as trisomy.-Alldred, M. J., Chao, H. M., Lee, S. H., Beilin, J., Powers, B. E., Petkova, E., Strupp, B. J., Ginsberg, S. D. Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Entities:  

Keywords:  early choline delivery; hippocampus; laser capture microdissection; microarray; trisomic

Mesh:

Substances:

Year:  2019        PMID: 31180719      PMCID: PMC6704451          DOI: 10.1096/fj.201802669RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  114 in total

1.  CSPα knockout causes neurodegeneration by impairing SNAP-25 function.

Authors:  Manu Sharma; Jacqueline Burré; Peter Bronk; Yingsha Zhang; Wei Xu; Thomas C Südhof
Journal:  EMBO J       Date:  2011-12-20       Impact factor: 11.598

2.  Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.

Authors:  Erik D Roberson; Brian Halabisky; Jong W Yoo; Jinghua Yao; Jeannie Chin; Fengrong Yan; Tiffany Wu; Patricia Hamto; Nino Devidze; Gui-Qiu Yu; Jorge J Palop; Jeffrey L Noebels; Lennart Mucke
Journal:  J Neurosci       Date:  2011-01-12       Impact factor: 6.167

3.  ATG4B (Autophagin-1) phosphorylation modulates autophagy.

Authors:  Zhifen Yang; Rachel P Wilkie-Grantham; Teruki Yanagi; Chih-Wen Shu; Shu-Ichi Matsuzawa; John C Reed
Journal:  J Biol Chem       Date:  2015-09-16       Impact factor: 5.157

4.  Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.

Authors:  A M Cataldo; C M Peterhoff; J C Troncoso; T Gomez-Isla; B T Hyman; R A Nixon
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

5.  Maternal choline supplementation programs greater activity of the phosphatidylethanolamine N-methyltransferase (PEMT) pathway in adult Ts65Dn trisomic mice.

Authors:  Jian Yan; Stephen D Ginsberg; Brian Powers; Melissa J Alldred; Arthur Saltzman; Barbara J Strupp; Marie A Caudill
Journal:  FASEB J       Date:  2014-06-24       Impact factor: 5.191

6.  Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD).

Authors:  Melissa J Alldred; Sang Han Lee; Eva Petkova; Stephen D Ginsberg
Journal:  Brain Struct Funct       Date:  2014-07-17       Impact factor: 3.270

Review 7.  Cell biology and function of neuronal ceroid lipofuscinosis-related proteins.

Authors:  Katrin Kollmann; Kristiina Uusi-Rauva; Enzo Scifo; Jaana Tyynelä; Anu Jalanko; Thomas Braulke
Journal:  Biochim Biophys Acta       Date:  2013-02-09

8.  Phosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial.

Authors:  Carol L Cheatham; Barbara Davis Goldman; Leslie M Fischer; Kerry-Ann da Costa; J Steven Reznick; Steven H Zeisel
Journal:  Am J Clin Nutr       Date:  2012-11-07       Impact factor: 7.045

Review 9.  Cerebal overinhibition could be the basis for the high prevalence of epilepsy in persons with Down syndrome.

Authors:  Bruno Henrique Silva Araujo; Laila Brito Torres; Laura Maria F F Guilhoto
Journal:  Epilepsy Behav       Date:  2015-11-08       Impact factor: 2.937

10.  LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation.

Authors:  Yukiko Kabeya; Noboru Mizushima; Akitsugu Yamamoto; Satsuki Oshitani-Okamoto; Yoshinori Ohsumi; Tamotsu Yoshimori
Journal:  J Cell Sci       Date:  2004-06-01       Impact factor: 5.285

View more
  9 in total

Review 1.  Endosomal-lysosomal dysfunctions in Alzheimer's disease: Pathogenesis and therapeutic interventions.

Authors:  Shereen Shi Min Lai; Khuen Yen Ng; Rhun Yian Koh; Kian Chung Chok; Soi Moi Chye
Journal:  Metab Brain Dis       Date:  2021-04-21       Impact factor: 3.584

Review 2.  Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease.

Authors:  Shampa Ghosh; Shantanu Durgvanshi; Shreya Agarwal; Manchala Raghunath; Jitendra Kumar Sinha
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

3.  Mitovesicles are a novel population of extracellular vesicles of mitochondrial origin altered in Down syndrome.

Authors:  Pasquale D'Acunzo; Rocío Pérez-González; Yohan Kim; Tal Hargash; Chelsea Miller; Melissa J Alldred; Hediye Erdjument-Bromage; Sai C Penikalapati; Monika Pawlik; Mitsuo Saito; Mariko Saito; Stephen D Ginsberg; Thomas A Neubert; Chris N Goulbourne; Efrat Levy
Journal:  Sci Adv       Date:  2021-02-12       Impact factor: 14.136

4.  The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome.

Authors:  Fiorenza Stagni; Beatrice Uguagliati; Marco Emili; Andrea Giacomini; Renata Bartesaghi; Sandra Guidi
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

Review 5.  Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules.

Authors:  Chiara Lanzillotta; Fabio Di Domenico
Journal:  Biomolecules       Date:  2021-02-11

Review 6.  Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer's Disease.

Authors:  Jose L Martinez; Matthew D Zammit; Nicole R West; Bradley T Christian; Anita Bhattacharyya
Journal:  Front Aging Neurosci       Date:  2021-07-12       Impact factor: 5.702

7.  Profiling Basal Forebrain Cholinergic Neurons Reveals a Molecular Basis for Vulnerability Within the Ts65Dn Model of Down Syndrome and Alzheimer's Disease.

Authors:  Melissa J Alldred; Sai C Penikalapati; Sang Han Lee; Adriana Heguy; Panos Roussos; Stephen D Ginsberg
Journal:  Mol Neurobiol       Date:  2021-07-14       Impact factor: 5.682

Review 8.  Choline, Neurological Development and Brain Function: A Systematic Review Focusing on the First 1000 Days.

Authors:  Emma Derbyshire; Rima Obeid
Journal:  Nutrients       Date:  2020-06-10       Impact factor: 5.717

9.  Maternal Choline Supplementation as a Potential Therapy for Down Syndrome: Assessment of Effects Throughout the Lifespan.

Authors:  Brian E Powers; Ramon Velazquez; Myla S Strawderman; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Front Aging Neurosci       Date:  2021-10-06       Impact factor: 5.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.